Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Clinical Ophthalmology

Volumn 9, Issue , 2015, Pages 633-643

  Quaranta, Luciano ^a   Riva, Ivano ^a   Katsanos, Andreas ^b   Floriani, Irene ^c   Centofanti, Marco ^d   Konstas, Anastasios G P ^e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF IOANNINA   (Greece)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Glaucoma; Ocular hypertension; Prostaglandin analogue

Indexed keywords

BENZALKONIUM CHLORIDE; BIMATOPROST; LATANOPROST; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

CLINICAL TRIAL (TOPIC); CONGENITAL GLAUCOMA; CONJUNCTIVAL HYPEREMIA; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; EYE IRRITATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRIS DISEASE; JUVENILE GLAUCOMA; META ANALYSIS (TOPIC); MONOTHERAPY; MORNING DOSAGE; NONHUMAN; OPEN ANGLE GLAUCOMA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRICHIASIS;

EID: 84929583840     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S61444     Document Type: Review

References (104)

1. Friedman DS, Wolfs RC, O’Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122(4):532–538.
2. Thylefors B, Négrel AD. The global impact of glaucoma. Bull World Health Organ. 1994;72(3):323–326.
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
4. Agarwal R, Gupta SK, Agarwal P, Saxena R, Agrawal SS. Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol. 2009;57(4):257–266.
5. Pillunat LE, Stodtmeister R, Marquardt R, Mattern A. Ocular perfusion pressures in different types of glaucoma. Int Ophthalmol. 1989;13(1–2):37–42.
6. Quaranta L, Manni G, Donato F, Bucci MG. The effect of increased intraocular pressure on pulsatile ocular blood flow in low tension glaucoma. Surv Ophthalmol. 1994;38 Suppl:S177–S181; discussion S182.
7. Quaranta L, Katsanos A, Russo A, Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58(1):26–41.
8. Grunwald JE, Sinclair SH, Riva CE. Autoregulation of the retinal circulation in response to decrease of intraocular pressure below normal. Invest Ophthalmol Vis Sci. 1982;23(1):124–127.
9. Pillunat LE, Anderson DR, Knighton RW, Joos KM, Feuer WJ. Autoregulation of human optic nerve head circulation in response to increased intraocular pressure. Exp Eye Res. 1997;64(5):737–744.
10. Ojha P, Wiggs JL, Pasquale LR. The genetics of intraocular pressure. Semin Ophthalmol. 2013;28(5–6):301–305.
11. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol. 2004;15(2):102–106.
12. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. Epub 2014 Dec 18.
13. Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol. 2013;131(12):1573–1582.
14. Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002;18(4):313–324.
15. Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003;44(2):715–721.
16. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53 Suppl 1:S69–S84.
17. Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester. Exp Eye Res. 1987;44(2):217–226.
18. Villumsen J, Alm A, Söderström M. Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma. Br J Ophthalmol. 1989;73(12):975–979.
19. Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17(5):421–432.
20. Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2007;1(1):11–24.
21. McCue BA, Cason MM, Curtis MA, Faulkner RD, Dahlin DC. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS. J Pharm Biomed Anal. 2002;28(2):199–208.
22. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53 Suppl 1:S107–S120.
23. Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J Glaucoma. 2005;14(1):70–73.
24. Toris CB, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma. 2007;16(2):189–195.
25. Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43(5):1475–1487.
26. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67(2):179–191.
27. Sagara T, Gaton DD, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117(6):794–801.
28. Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36(12):2461–2465.
29. Alphen GW, Wilhelm PB, Elsenfeld PW. The effect of prostaglandins on the isolated internal muscles of the mammalian eye, including man. Doc Ophthalmol. 1977;42(2):397–415.
30. Stjernschantz J, Selén G, Ocklind A, Resul B. Effects of latanoprost and related prostaglandin analogues. In: Alm, Weinreb RN, editors. Uveoscleral Outflow. Biology and Clinical Aspects. London, UK: Mosby International Limited; 1998:57–72.
31. Gaton DD, Sagara T, Lindsey JD, Gabelt BT, Kaufman PL, Weinreb RN. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol. 2001;119(8):1165–1170.
32. Husain S, Jafri F, Crosson CE. Acute effects of PGF2alpha on MMP-2 secretion from human ciliary muscle cells: a PKC- and ERK-dependent process. Invest Ophthalmol Vis Sci. 2005;46(5):1706–1713.
33. Lutjen-Drecoll E, Tamm E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp Eye Res. 1988;47(5):761–769.
34. Nilsson SF, Drecoll E, Lütjen-Drecoll E, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 2006;47(9):4042–4049.
35. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci. 2003;44(10):4419–4426.
36. Krebs W, Krebs IP. Ultrastructural evidence for lymphatic capillaries in the primate choroid. Arch Ophthalmol. 1988;106(11):1615–1616.
37. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32(1):172–180.
38. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39(13):2649–2658.
39. Vaajanen A, Vapaatalo H, Oksala O. A modified in vitro method for aqueous humor outflow studies in enucleated porcine eyes. J Ocul Pharmacol Ther. 2007;23(2):124–131.
40. Bahler CK, Howell KG, Hann CR, Fautsch MP, Johnson DH. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol. 2008;145(1):114–119.
41. Zhao X, Pearson KE, Stephan DA, Russell P. Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2003;44(5):1945–1952.
42. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47 Suppl 1:S105–S115.
43. Holmstrom S, Buchholz P, Walt J, Wickstrøm J, Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005;21(11):1875–1883.
44. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112(7):1177–1185.
45. Konstas AG, Mikropoulos D, Kaltsos K, Jenkins JN, Stewart WC. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology. 2006;113(3):446–450.
46. Konstas AG, Mikropoulos D, Haidich AB, Ntampos KS, Stewart WC. Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br J Ophthalmol. 2009;93(4):481–485.
47. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115(7):1117–1122.e1.
48. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004;26(1):84–91.
49. Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540.
50. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10(5):414–422.
51. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109(5):998–1008.
52. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472–484.
53. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140(1):1–7.
54. Li N, Chen XM, Zhou Y, Wei ML, Yao X. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol. 2006;34(8):755–764.
55. Holló G, Thelen U, Teus MA, et al. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. J Ocul Pharmacol Ther. 2011;27(5):493–498.
56. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688–703.
57. Noecker RJ, Earl ML, Mundorf T, Peace J, Williams RD. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther. 2003;20(2):121–128.
58. Cardascia N, Vetrugno M, Trabucco T, Cantatore F, Sborgia C. Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. Curr Ther Res Clin Exp. 2003;64(7):389–400.
59. Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007;114(4):653–657.
60. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y, Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90(11):1370–1373.
61. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–713; discussion 829–830.
62. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392–399.
63. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242–250.
64. Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389.
65. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205–215.
66. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115(1):109–115.
67. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112(11):1437–1445.
68. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980;25(1):15–30.
69. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma. 2003;12(6):486–490.
70. Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study. J Glaucoma. 2013;22(9):730–735.
71. Brignole-Baudouin F, Riancho L, Liang H, Baudouin C. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res. 2011;36(11):979–988.
72. Liang H, Brignole-Baudouin F, Riancho L, Baudouin C. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions. Ophthalmic Res. 2012;48(2):89–101.
73. Choy CK, Cho P, Boost MV. Cytotoxicity and effects on metabolism of contact lens care solutions on human corneal epithelium cells. Clin Exp Optom. 2012;95(2):198–206.
74. Choy CK, Cho P, Boost MV, Benzie IF. Do multipurpose solutions damage porcine corneal epithelial cells? Optom Vis Sci. 2009;86(5):E447–E453.
75. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16(1):98–103.
76. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2(3):613–621.
77. Fukuchi T, Wakai K, Suda K, et al. Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications. Clin Ophthalmol. 2010;4:203–209.
78. Alcon Research. Travoprost 3-Month Safety and Efficacy Study. Available from: https://clinicaltrials.gov/show/NCT01453855. NLM Identifier: NCT01453855. Accessed January 17, 2014.
79. Alcon Research. Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients. Available from: https://clinicaltrials.gov/show/NCT01652664. NLM Identifier: NCT01652664. Accessed January 17, 2014.
80. Yanovitch TL, Enyedi LB, Schotthoeffer EO, Freedman SF. Travoprost in children: adverse effects and intraocular pressure response. J AAPOS. 2009;13(1):91–93.
81. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53 Suppl 1:S93–S105.
82. Astin M, Stjernschantz J, Selén G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59(4):401–407.
83. Astin M, Stjernschantz J. Mediation of prostaglandin f2 alpha-induced ocular surface hyperemia by sensory nerves in rabbits. Curr Eye Res. 1997;16(9):886–890.
84. Astin M, Stjernschantz J. Mechanism of prostaglandin E2-, F2alpha- and latanoprost acid-induced relaxation of submental veins. Eur J Pharmacol. 1997;340(2–3):195–201.
85. Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol. 2004;51(5 Suppl):S149–S150.
86. Colombe L, Michelet JF, Bernard BA. Prostanoid receptors in anagen human hair follicles. Exp Dermatol. 2008;17(1):63–72.
87. Bearden W, Anderson R. Trichiasis associated with prostaglandin analog use. Ophthal Plast Reconstr Surg. 2004;20(4):320–322.
88. Hart J, Shafranov G. Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost. Am J Ophthalmol. 2004;137(4):756–757.
89. O’Toole L, Cahill M, O’Brien C. Eyelid hypertrichosis associated with latanoprost is reversible. Eur J Ophthalmol. 2001;11(4):377–379.
90. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41 Suppl 2:S129–S138.
91. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004;122(7):957–965.
92. Imesch PD, Bindley CD, Khademian Z, et al. Melanocytes and iris color. Electron microscopic findings. Arch Ophthalmol. 1996;114(4):443–447.
93. Prota G, Vincensi MR, Napolitano A, Selen G, Stjernschantz J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 2000;13(3):147–150.
94. Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res. 1999;69(4):431–436.
95. Smith-Thomas L, Moustafa M, Spada CS, et al. Latanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependent. Exp Eye Res. 2004;78(5):973–985.
96. Del Hierro Zarzuelo A, Martínez de la Casa JM, García Feijoó J, Castillo Gómez A, Méndez Hernández C, García Sánchez J. [Cystoid macular edema induced by travoprost]. Arch Soc Esp Oftalmol. 2004;79(6):295–297. Spanish.
97. Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123(2):186–192.
98. Esquenazi S. Cystoid macular edema in a pseudophakic patient after switching from latanoprost to BAK-free travoprost. J Ocul Pharmacol Ther. 2007;23(6):567–570.
99. Faulkner WJ, Burk SE. Acute anterior uveitis and corneal edema associated with travoprost. Arch Ophthalmol. 2003;121(7):1054–1055.
100. Kumarasamy M, Desai SP. Anterior uveitis is associated with travoprost. BMJ. 2004;329(7459):205.
101. Suominen S, Välimäki J. Bilateral anterior uveitis associated with travoprost. Acta Ophthalmol Scand. 2006;84(2):275–276.
102. Aydin S, Ozcura F. Corneal oedema and acute anterior uveitis after two doses of travoprost. Acta Ophthalmol Scand. 2007;85(6):693–694.
103. Chiam P. Travoprost induced granulomatous anterior uveitis. Case Rep Ophthalmol Med. 2011;2011:507073.
104. Cellini M, Caramazza R, Bonsanto D, Bernabini B, Campos EC. Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study. Ophthalmologica. 2004;218(5):312–317.